OpenOnco
UA EN

Onco Wiki / Biomarker

Germline CDH1 pathogenic variant

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDBIO-CDH1-GERMLINE
TypeBiomarker
Aliases
E-cadherin germline mutationGermline CDH1 mutation (HDGC syndrome)HDGCgCDH1Зародкова патогенна варіація CDH1
Statusreviewed 2026-04-29 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-CIVIC SRC-NCCN-BREAST-2025 SRC-NCCN-GASTRIC-2025

Biomarker Facts

Biomarker typegene_mutation
Mutation details{"functional_impact": "loss of E-cadherin — cell-adhesion failure → diffuse-pattern epithelial cancers", "gene": "CDH1", "inheritance": "germline", "variant_type": "loss-of-function (frameshift, nonsense, splice, large deletions)"}
Measurement
MethodGermline multi-gene hereditary-cancer NGS panel on whole blood or saliva. Large-deletion / MLPA testing required (single-exon and whole-gene deletions are recurrent and missed by short-read NGS alone).
Unitscategorical: pathogenic | likely_pathogenic | VUS | benign | absent
Related biomarkersBIO-BRCA-GERMLINE BIO-BRCA1-BRCA2-GERMLINE

Notes

Surveillance / prophylaxis biomarker — not a therapy-selection biomarker in v0.1. Engine should surface CDH1+ status under "hereditary syndrome — referral to genetics" rather than treatment branches. Lobular breast subtype + family history of diffuse gastric cancer is a strong testing trigger even without other red flags.

Used By

Red flag